ArticleMolecular metabolism2014
Acute mTOR inhibition induces insulin resistance and alters substrate utilization in vivo.
Article in Molecular metabolism, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 81 citations in OpenAlex.
- Bench to bedside: is rapamycin headed for the docTOR?GeroScience · 2026Review
- Cell-intrinsic mTOR/LET-363 influences morphological aging of the ALM touch receptor neuron in Caenorhabditis elegans.PloS one · 2026Article
- mTOR signaling networks: mechanistic insights and translational frontiers in disease therapeutics.Signal transduction and targeted therapy · 2025Review
- Treatment with L-type amino acid transporter 1 inhibitor JPH203 enhances protein synthesis in C2C12 myotubes.Scientific reports · 2025Article
- Coordinated Regulation of Renal Glucose Reabsorption and Gluconeogenesis by mTORC2 and Potassium.Journal of the American Society of Nephrology : JASN · 2025Article
- Review
- Pantothenate kinase 4 controls skeletal muscle substrate metabolism.Nature communications · 2025Article
- The Interlinking Metabolic Association between Type 2 Diabetes Mellitus and Cancer: Molecular Mechanisms and Therapeutic Insights.Diagnostics (Basel, Switzerland) · 2024Review
- Medication-Induced Hyperglycemia and Diabetes Mellitus: A Review of Current Literature and Practical Management Strategies.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024Review
- Associations between Diabetes Mellitus and Selected Cancers.International journal of molecular sciences · 2024Review
- Geroprotector drugs and exercise: friends or foes on healthy longevity?BMC biology · 2023Review
- Enrichr-KG: bridging enrichment analysis across multiple libraries.Nucleic acids research · 2023Article
- mTORC1 beyond anabolic metabolism: Regulation of cell death.The Journal of cell biology · 2022Review
- Importance of Insulin Resistance in the COVID-19 Era: A Retrospective Analysis of a Single Center in Mexico.Cureus · 2022Article
- Clenbuterol exerts antidiabetic activity through metabolic reprogramming of skeletal muscle cells.Nature communications · 2022Article
- Queueing theory model of mTOR complexes' impact on Akt-mediated adipocytes response to insulin.PloS one · 2022Article
- Exercise increases phosphorylation of the putative mTORC2 activity readout NDRG1 in human skeletal muscle.American journal of physiology. Endocrinology and metabolism · 2022Article
- The Relationship Between Diabetes Mellitus and Cancers and Its Underlying Mechanisms.Frontiers in endocrinology · 2022Review
- Dissecting the biology of mTORC1 beyond rapamycin.Science signaling · 2021Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The effect of acute inhibition of both mTORC1 and mTORC2 on metabolism is unknown. A single injection of the mTOR kinase inhibitor, AZD8055, induced a transient, yet marked increase in fat oxidation and insulin resistance in mice, whereas the mTORC1 inhibitor rapamycin had no effect. AZD8055, but not rapamycin reduced insulin-stimulated glucose uptake into incubated muscles, despite normal GLUT4 translocation in muscle cells. AZD8055 inhibited glycolysis in MEF cells. Abrogation of mTORC2 activity by SIN1 deletion impaired glycolysis and AZD8055 had no effect in SIN1 KO MEFs. Re-expression of wildtype SIN1 rescued glycolysis. Glucose intolerance following AZD8055 administration was absent in mice lacking the mTORC2 subunit Rictor in muscle, and in vivo glucose uptake into Rictor-deficient muscle was reduced despite normal Akt activity. Taken together, acute mTOR inhibition is detrimental to glucose homeostasis in part by blocking muscle mTORC2, indicating its importance in muscle metabolism in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.